Pathology, research and practice · 2023
miRNAs driving diagnosis, progression, and drug resistance in multiple myeloma.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elkady Mohamed A, Yehia Amr Mohamed, Elsakka Elsayed G E, Abulsoud Ahmed I, Abdelmaksoud Nourhan M, Elshafei Ahmed, Elkhawaga Samy Y, Ismail Ahmed, Mokhtar Mahmoud Mohamed, El-Mahdy Hesham A, Hegazy Maghawry, Elballal Mohammed S, Mohammed Osama A, El-Husseiny Hussein M, Midan Heba M, El-Dakroury Walaa A, Zewail Moataz B, Abdel Mageed Sherif S, Doghish Ahmed S
Аннотация
Multiple myeloma (MM) is a tumor of transformed plasma cells. It's the second most common hematologic cancer after non-Hodgkin lymphoma. MM is a complex disease with many different risk factors, including ethnicity, race, and epigenetics. The microRNAs (miRNAs) are a critical epigenetic factor in multiple myeloma, influencing key aspects such as pathogenesis, prognosis, and resistance to treatment. They have the potential to assist in disease diagnosis and modulate the resistance behavior of MM towards therapeutic regimens. These characteristics could be attributed to the modulatory effects of miRNAs on some vital pathways such as NF-KB, PI3k/AKT, and P53. This review discusses the role of miRNAs in MM with a focus on their role in disease progression, diagnosis, and therapeutic resistance.